← back to search

Andrea Mambrini

University of Pisa · IT
Area of research
Oncology · Hepatology
Research interest
Research interests include Pancreatic and Hepatic Oncology Research, Hepatocellular Carcinoma Treatment and Prognosis, Cholangiocarcinoma and Gallbladder Cancer Studies, and Cancer Genomics and Diagnostics.
h-index
33
citations
4,489
works
227
NIH funding
primary concept
Medicine
email

Recent publications

Potential association between <scp> <i>PSCA</i> rs2976395 </scp> functional variant and pancreatic cancer risk
International Journal of Cancer 2024cited by 4position: middledoi
A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma
Mutagenesis 2024cited by 2position: middledoi
The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years’ experience of association studies to understand the genetic architecture of pancreatic cancer
Critical Reviews in Oncology/Hematology 2023cited by 36position: middledoi
Genetic and non-genetic risk factors for early-onset pancreatic cancer
Digestive and Liver Disease 2023cited by 36position: middledoi
Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma
Journal of Medical Genetics 2023cited by 22position: middledoi
Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians
Biological Research 2023cited by 2position: middledoi
Association between a polymorphic variant in the <i>CDKN2B‐AS1/ANRIL</i> gene and pancreatic cancer risk
International Journal of Cancer 2022cited by 18position: middledoi
Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk
Frontiers in Genetics 2021cited by 20position: middledoi
Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk
Frontiers in Oncology 2021cited by 12position: middledoi
Association of genetic variants affecting microRNAs and pancreatic cancer risk
Pancreatology 2021cited by 3position: middledoi
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
The Lancet Oncology 2020cited by 321position: middledoi
Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction
Journal of Medical Genetics 2020cited by 71position: middledoi
Germline <i>BRCA2</i> K3326X and <i>CHEK2</i> I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma
International Journal of Cancer 2019cited by 31position: middledoi
Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer
Nature Communications 2018cited by 278position: middledoi
Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study
International Journal of Cancer 2018cited by 56position: middledoi
Genetic variability of the ABCC2 gene and overall survival in pancreatic cancer
Pancreatology 2018cited by 1position: middledoi
SLC22A3 polymorphisms may influence overall patient survival- PANDORA study
Pancreatology 2018cited by 0position: middledoi
SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival
Scientific Reports 2017cited by 18position: middledoi
Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation
International Journal of Cancer 2017cited by 17position: middledoi
Genetic determinants of telomere length and risk of pancreatic cancer: a PANDoRA study
Pancreatology 2017cited by 2position: middledoi
Rare BRCA2 K3326X increases susceptibility to sporadic pancreatic ductal adenocarcinoma: A PANDoRA study
Pancreatology 2017cited by 0position: middledoi
Abstract 3411: Rare BRCA2 K3326X increases susceptibility to sporadic pancreatic ductal adenocarcinoma: a PANDoRA study
Cancer Research 2017cited by 0position: middledoi
Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21
Oncotarget 2016cited by 112position: middledoi
Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk
Oncotarget 2016cited by 56position: middledoi
Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients
Carcinogenesis 2016cited by 21position: middledoi
Functional polymorphisms in the CDKN2A- CDKN2B gene regions affect pancreatic cancer risk
Pancreatology 2016cited by 0position: middledoi
Functional polymorphisms in the CDKN2A generegion affect pancreatic cancer risk
Pancreatology 2016cited by 0position: middledoi
Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer
Nature Genetics 2015cited by 270position: middledoi
<scp><i>TERT</i></scp> gene harbors multiple variants associated with pancreatic cancer susceptibility
International Journal of Cancer 2015cited by 76position: middledoi
Novel pancreatic cancer susceptibility loci discovered through genome-wide association studies
Pancreatology 2015cited by 0position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Pavel Souček · Charles University4 papers (2016–2017)Federico Canzian · German Cancer Research Center4 papers (2016–2017)Pavel Vodička · Czech Academy of Sciences4 papers (2016–2017)Maria Gazouli · National and Kapodistrian University of Athens4 papers (2016–2017)Juozas Kupčinskas · Johannes Gutenberg University Mainz4 papers (2016–2017)Daniele Campa · University of Pisa4 papers (2016–2017)Hermann Brenner · Stanford University4 papers (2016–2017)Thilo Hackert · HAW Hamburg3 papers (2016–2017)Aldo Scarpa · Cancer Research UK Manchester Centre3 papers (2016–2017)Giulia Martina Cavestro · LMU Klinikum3 papers (2016–2017)Raffaele Pezzilli · Ospedale San Carlo3 papers (2016–2017)Gabriele Capurso · Vita-Salute San Raffaele University2 papers (2016–2017)Ugo Boggi · California University of Pennsylvania2 papers (2017–2017)Anna Caterina Milanetto · University of Padua2 papers (2016–2016)Renata Talar‐Wojnarowska · Medical University of Lodz2 papers (2016–2016)Frederike Dijk · Dutch Cancer Society2 papers (2016–2016)Ofure Obazee · German Cancer Research Center2 papers (2017–2017)Manuel Gentiluomo · University of Pisa2 papers (2016–2016)Francesca Tavano · University of Padua2 papers (2016–2016)Yogesh K. Vashist · Społeczna Akademia Nauk2 papers (2016–2016)